Lynn M. Schuchter

Lynn M. Schuchter

Hematology | Oncology
3400 Civic Center Boulevard
West Pavilion, 3rd Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 146 publications

Accuracy of Sentinel Lymph Node Biopsy to Predict Nodal Metastasis in Head and Neck Merkel Cell Carcinoma.

Accuracy of Sentinel Lymph Node Biopsy to Predict Nodal Metastasis in Head and Neck Merkel Cell Carcinoma.

Journal: JAMA otolaryngology-- head & neck surgery
Published: January 29, 2026

Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy.

Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy.

Journal: The oncologist
Published: November 07, 2025

ASO Visual Abstract: Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma.

ASO Visual Abstract: Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma.

Journal: Annals of surgical oncology
Published: October 08, 2025

Topical Resiquimod Elicits Systemic Protection and Improves Anti-PD-1 Therapy in Melanoma via Priming of CD8+ T Cells.

Topical Resiquimod Elicits Systemic Protection and Improves Anti-PD-1 Therapy in Melanoma via Priming of CD8+ T Cells.

Journal: Cancer immunology research
Published: August 11, 2025

Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma.

Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma.

Journal: Annals of surgical oncology
Published: July 24, 2025

A Text Message Intervention to Minimize the Time Burden of Cancer Care.

A Text Message Intervention to Minimize the Time Burden of Cancer Care.

Journal: NEJM catalyst innovations in care delivery
Published: July 22, 2025

Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations.

Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations.

Journal: Cell reports
Published: July 17, 2025

DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity.

DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 12, 2025

Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade.

Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade.

Journal: Cancer cell
Published: January 19, 2025

Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells.

Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells.

Journal: Science advances
Published: January 15, 2025

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group.

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 04, 2024

Clinician- and Patient-Directed Communication Strategies for Patients With Cancer at High Mortality Risk: A Cluster Randomized Trial.

Clinician- and Patient-Directed Communication Strategies for Patients With Cancer at High Mortality Risk: A Cluster Randomized Trial.

Journal: JAMA network open
Published: July 01, 2024
Showing 1-12 of 146

Last Updated: 09/26/2026